https://charts.traderzeitung.de/phases/US86366E1064
string(1435) "{"isin":"US86366E1064","name":"Structure Therapeutics Inc","stock_id":36741005,"generated_at":"2026-10-22 04:49:00","days":[{"date":"2026-10-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":21.2,"close_at":"2026-10-19 14:02:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":21.99,"close_at":"2026-10-19 21:59:00","complete":true,"perf_pct":3.7264},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":22.2,"close_at":"2026-10-20 14:04:00","complete":true,"perf_pct":0.955},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":22.89,"close_at":"2026-10-20 21:59:00","complete":true,"perf_pct":3.1081},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":23.16,"close_at":"2026-10-20 23:31:00","complete":true,"perf_pct":1.1796}]},{"date":"2026-10-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":22.04,"close_at":"2026-10-21 21:59:00","complete":true,"perf_pct":-4.8359},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Structure Therapeutics Aktie News & Nachrichten
Trading-Room

Structure Therapeutics Aktie News & Nachrichten

[WKN: A3D5Y7 | Symbol: GPCR]
Realtimekurs
   
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Structure Therapeutics

Structure Therapeutics: Einzigartige Wirksamkeit - Wird Aleniglipron zum oralen GLP-1-Durchbruch?

GLP-1-Rezeptoragonisten gehören zu den aktuell umsatzstärksten Medikamentenklassen der Welt – insbesondere...

Structure Therapeutics (GPCR): H.C. Wainwright sieht 208 % Kurspotenzial mit Verweis auf die differenzierten Gewichtsverlust-Ergebnisse!

Structure Therapeutics Inc. (GPCR) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung...

Structure Therapeutics (GPCR): H.C. Wainwright sieht in der Behandlung von Adipositas für den Biotech 141 % Kurspotenzial

Structure Therapeutics Inc. (GPCR) ist ein Biopharmaunternehmen, das innovative orale Therapeutika für...

TOP-5-Kursziele der Analysten am 04.12.24

CleanSpark [US18452B2097]: H.C. Wainwright bekräftigt Kaufempfehlung mit Kursziel 27 USD (91 % Kurspotenzial)...

  • ‹
  • 1
  • ›
Structure Therapeutics Nachrichtenticker öffnen
MT Newswires 08.09.2026 19:30 Uhr

Structure Therapeutics meldet Gewichtsverlust von bis zu 16,2% in Aleniglipron-Studie

01:29 PM EDT, 09/08/2026 (MT Newswires) -- Structure Therapeutics (GPCR) teilte am Dienstag mit, dass eine Einzeldosis seines Medikamentenkandidaten A